

Article type : Supplement Article

R3 March 6, 2019

***SCN8A* encephalopathy: Mechanisms and Models**

Miriam Meisler, Ph. D.  
Department of Human Genetics  
University of Michigan  
Ann Arbor, MI 48109

Contact information for corresponding author:

Miriam H. Meisler  
Department of Human Genetics Box 5618  
University of Michigan  
Ann Arbor, Michigan 48109-5618  
tel 734 763 5546; FAX 734 763 9691  
meislerm@umich.edu

Running title : Mechanisms of *SCN8A* encephalopathy

Key words for use by abstracting services:

*SCN8A*, encephalopathy, mutation, sodium channel, mouse model

Number of text pages: 10

Number of words (summary): 126

Number of words (main text); 1,682

Number of tables: 1

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/EPI.14703](https://doi.org/10.1111/EPI.14703)

This article is protected by copyright. All rights reserved

Number of figures : 6; color not essential

\* *De novo* GOF mutations in *SCN8A* encephalopathy alter the biophysical properties of sodium channel Nav1.6 and result in neuronal hyperexcitability.

\* Functional effects of pathogenic mutations include impaired channel inactivation, premature channel opening, and elevated persistent current.

\* Mouse lines expressing the *SCN8A* patient mutations p.Asn1768Asp and p.Arg1872Trp recapitulate the human disorder with spontaneous seizures and premature lethality.

\* Conditional expression of p.Arg1872Trp in excitatory forebrain neurons causes seizures and premature lethality but expression in inhibitory neurons is nonpathogenic.

\* Loss-of-function variants of *SCN8A* are less severe clinically, resulting in isolated intellectual disability, myoclonus, or mild seizure disorders.

**Summary:**

*De novo* mutations of the neuronal sodium channel *SCN8A* have been identified in approximately 2% of individuals with epileptic encephalopathy. These missense mutations alter the biophysical properties of sodium channel Nav1.6 in ways that lead to neuronal hyperexcitability. We generated two mouse models carrying patient mutations N1768D and R1872W in order to characterize the effects on neuronal function *in vivo*. The conditional R1872W mutation is activated by expression of CRE recombinase, permitting characterization of the effects of the mutation on different classes of neurons and at different points in postnatal development. Preclinical drug testing in these mouse models provides support for several new therapies for this devastating disorder. Mutations of *SCN8A* that result in partial or complete loss-of-function are associated with intellectual disability and other disorders.

**key words:** *SCN8A*, encephalopathy, mutation, sodium channel, mouse model

**Introduction:**

The sodium channel gene *SCN8A* was first identified by molecular analysis of spontaneous neurological mutants in the mouse. Positional cloning and genome sequencing of mouse *Scn8a* from mutant lines identified two protein truncation mutations, a splice site mutation and a missense mutation, that were responsible for movement disorders ranging from tremor, ataxia, and dystonia to hind limb paralysis and lethality<sup>1-3</sup>. These spontaneous mouse mutations resulted in partial or complete loss of function of the sodium channel Nav1.6 and exhibited recessive inheritance and the absence of spontaneous tonic/clonic seizures. two sentences deleted here

The first human epileptogenic *SCN8A* mutation was described in 2012<sup>4</sup>. Michael Hammer at the University of Arizona carried out complete genome sequencing of two parents, an affected child, and an unaffected sibling. A *de novo* A>G mutation was identified in the affected daughter, resulting in the *SCN8A* missense mutation p.Asn1768Asp (N1768D)<sup>4</sup>. To assess the pathogenicity of this mutation, we introduced it into a Nav1.6 cDNA and carried out functional evaluation in transfected ND7/23 cells. We observed a large increase in persistent current resulting in elevated firing of transfected neurons<sup>4</sup>. The causal role of the *SCN8A* mutation was confirmed in a knock-in mouse model that recapitulated epilepsy and sudden death<sup>5</sup>.

The important role of *SCN8A* in epileptic encephalopathy was quickly confirmed in additional patients. Today nearly 300 individuals with *SCN8A* encephalopathy have been reported in publications or described in databases maintained by family groups (e.g. [www.SCN8A.net](http://www.SCN8A.net)). Like the first case, the subsequently identified mutations arose *de novo* in the affected children, and result in missense substitutions of evolutionarily conserved amino acid residues that alter channel function<sup>6</sup>. The patient mutations are concentrated in transmembrane segments of the Nav1.6 channel protein, the inactivation gate and the cytoplasmic C-terminal domain (**Figure 1**).

Functional studies of approximately 20 patient mutations have been carried out by expression in transfected cells, and 2 mutations have been studied in neurons of knock-in mice. None of the *SCN8A* encephalopathy mutations result in protein truncation or loss of channel function. Rather, these are missense mutations that alter the biophysical properties of the channel, such as altered voltage dependence of channel activation or inactivation, delayed channel inactivation, or increased resurgent or persistent current. Most mutations change more than one parameter, making it difficult to assign relative 'severity'. The most common changes are a hyperpolarized shift in voltage dependence of activation, impaired channel inactivation, and elevated persistent current<sup>6</sup>. Each of these results in elevated neuronal firing, consistent with *in vivo* seizures.

Approximately 1/3 of the patient mutations in *SCN8A* encephalopathy occur at recurrent positions, many of which are located in CpG islands that are sites of elevated mutation rate in the human genome<sup>7</sup>. Arginine residues such as 1617 and 1872 are the sites of recurrent mutations which can have dramatic effects on channel function. For example, loss of the positive charge at Arg1872 due to substitution of either of three neutral amino acids results in destabilization of the inactive state of the channel, resulting in elevated neuronal excitability<sup>8</sup>.

We have generated two *in vivo* mouse models expressing patient mutations, the original mutation Asn1768Asp (N1768D)<sup>5</sup> and the recurrent mutation Arg1872Trp (R1872W)<sup>9</sup>. Both mice recapitulate the basic features of encephalopathy with spontaneous seizures and premature lethality. These mice enabled us to probe the effect of the mutations on firing patterns of different classes of mutations, secondary effects on expression of other genes, effects of *Scn8a* on cardiac function and responses to new drug therapies. The effects of strain background on seizure severity have also been examined. The features of the two mouse models are compared in **Table 1**.

### **The N1768D mouse model of *SCN8A* encephalopathy.**

We used targeting with a TALEN endonuclease to knock-in the patient mutation SCN8A-N1768D into exon 26 of the mouse *Scn8a* gene<sup>10</sup>. Spontaneous seizures were observed in heterozygous adults beginning at 2 months of age. Mice are highly sensitive to

gain-of-function mutations of *Scn8a*, and the time from first observed seizure to death varies from only one to four weeks depending on strain background (**Figure 2**).

Recordings from hippocampal neurons revealed spontaneous firing in subsets of CA1 and CA3 neurons<sup>11</sup> (**Figure 3**). Elevated activity was also observed in neurons from the medial entorhinal cortex that innervate the hippocampus<sup>12</sup>. Although Nav1.6 is expressed at a much lower level in cardiac myocytes, this expression is sufficient to generate cardiac arrhythmia in the N1768D mice<sup>13,14</sup>.

Secondary effects on gene expression were investigated by sequence analysis of transcripts from three brain regions, forebrain, cerebellum and hind brain<sup>15</sup>. Prior to seizure onset, we did not detect differences in transcript abundance between wildtype and mutant mice. Within 24 hours of the first observed seizure, there was elevation of transcripts associated with gliosis such as GFAP as well as neuropeptides previously associated with seizure susceptibility such as galanin and NPY<sup>15</sup>. We also observed a significant elevation of the neuropeptide NPW. These changes did not occur in mutant mice that did not develop seizures as a consequence of the incomplete penetrance of the N1768D mutation. We did not observe any compensatory up- or down-regulation of transcripts encoding other voltage-gated sodium channels, including *Scn1a*, *Scn2a* and *Scn3a*. The data suggest that there is not extensive remodeling of the brain via altered transcription prior to seizure onset.

### **The R1872W mouse model of *SCN8A* encephalopathy.**

We used the same TALEN reagent to target exon 26 of mouse *Scn8a* to generate the R1872W mutant mouse line, but in this case the mutation is dependent on expression of CRE recombinase<sup>9</sup>. The targeting vector containing two copies of exon 26 is shown in **Figure 4A**. In the absence of CRE, the mice express a full diploid dose of Nav1.6 that contains wildtype exon 26a. Expression of CRE recombinase results in deletion of exon 26a and initiates expression of exon 26b containing the R1872W mutation (**Figure 4B**).

We observed dramatic results of global activation of the mutant channel early in development by EIIA-CRE, with sudden onset of seizures at 14 days of age and death within 24 hours of the first observed seizures (**Figure 5**). Activation of R1872W specifically in excitatory neurons of the forebrain was sufficient to initiate seizures and death (**Figure 5**). Activation of R1872W exclusively in inhibitory neurons using GAD2 CRE or DLX5a CRE was

not pathogenic (**Figure 5**). Expression of the mutant channel in the adult by tamoxifen treatment of mice expressing the CAG-CRE-ER also resulted in 100% penetrance of spontaneous seizures and sudden death, demonstrating the continued sensitivity of adult neurons and an apparent cell-autonomous effect of the mutant channel in the mature CNS<sup>9</sup>.

These results are consistent with the major role of Nav1.6 in the initiation of action potentials at the AIS of excitatory neurons, and the elevated excitability of neurons expressing the mutant channel. This is in striking contrast with the Dravet Syndrome mouse, in which *inhibitory* neurons appear to be the primary target responsible for seizure initiation due to *reduced* activity of *Scn1a* (Ref.16).

Survival is approximately 4 weeks longer in mice expressing the Emx1-CRE compared with the ubiquitously expressed EIIA-CRE. This may be explained by the expression of the EIIA-CRE in many cells that do not express Emx1-CRE, including neurons in the brain stem that regulate respiration and cardiac function, as well as cardiac myocytes that express Nav1.6 at a low level<sup>13,14</sup>.

#### **Pre-clinical drug testing in the *SCN8A* mutant mice.**

Existing anti-epileptic drugs are inadequate for seizure control in the majority of children with epileptic encephalopathy. The availability of mouse mutants expressing patient mutations has made it possible to evaluate new therapeutic approaches. The polycyclic sodium channel modulator GS967/Prax330 acts to reduce persistent current<sup>17</sup>. Nav1.6 contributes to persistent current in CNS neurons, as demonstrated by the reduced persistent current in hippocampal CA1 neurons<sup>18</sup>, cerebellar granule cells<sup>19</sup>, and trigeminal mesencephalic neurons<sup>20</sup> from *Scn8a* null mice. Administration of GS967/Prax330 in the food to *Scn8a* N1768D/+ mice rescues lethality and reduces the incidence of spontaneous seizures by more than 50%<sup>21</sup> (**Figure 6**). The compound is also effective in mice with mutations of *Scn1a* and *Scn2a*<sup>17,22</sup>, possibly through its effect on wildtype Nav1.6. Phase 1 clinical trials of this compound are in progress.

A series of compounds with preferential effects on Nav1.6 developed by Xenon Pharmaceuticals are in Phase 1 clinical trials. previous sentence modified Antisense oligonucleotides that reduce transcript abundance are a potential third route to protection against gain-of-function mutations in *SCN8A*<sup>23</sup>; this approach is potentially applicable to *SCN8A* encephalopathy and testable in the mutant mice.

### **Summary of mouse models.**

Investigation of two mouse models has clearly demonstrated that gain-of-function mutations of *SCN8A* are sufficient to generate severe seizures and a lethal phenotype. Neurons from mutant mice exhibit hyperactivity, with greater severity and earlier lethality in the R1872W mutant. These mice have been used for pre-clinical evaluation of new drugs, accelerating progress to clinical trials. Analysis of the conditional R1872W mutant mouse demonstrated the specific role of excitatory neurons in *SCN8A* encephalopathy, in contrast to the key role of inhibitory neurons in Dravet Syndrome. The susceptibility of the adult nervous system to activation of the R1872W allele observed in the conditional mouse model indicates that life-long treatment will be required to protect against the effects of gain-of-function *SCN8A* alleles in the CNS.

### **The expanding spectrum of SCN8A disorders.**

The addition of *SCN8A* into gene testing panels and the increase in exome sequencing is resulting in the association of *SCN8A* with a broader spectrum of clinical conditions<sup>24-27</sup>, and this growth is likely to continue. Protein truncation mutations and missense mutations resulting in complete loss of channel activity have been identified in individuals with intellectual disability unaccompanied by seizures<sup>26,28</sup>. Partial loss of channel activity was identified in a family with the *SCN8A* mutation that segregated with isolated myoclonus<sup>27</sup>. We anticipate the future discovery of many more mutations in patients with movement disorders like those seen in the spontaneous mouse *Scn8a* mutants, such as ataxia, dystonia and essential tremor<sup>29</sup>.

**Acknowledgements:** Our work on *SCN8A* has been supported by NIH R01 NS034509 and by the Dravet Syndrome Foundation, the Wishes for Elliott Foundation and the Cute Syndrome Foundation. I thank Dr. Jacy Wagnon for helpful discussions.

**Ethical publication:** I confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

**Disclosure:** The author has no conflict of interest to disclose.

### References

1. Burgess DL, Kohrman DC, Galt J, et al. Mutation of a new sodium channel gene, Scn8a, in the mouse mutant 'motor endplate disease'. *Nature Genetics* 1995;10:461-465, 1995.
2. Kohrman DC, Harris JB, Meisler MH. Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT-AC intron. *J Biol Chem* 1996a;271:17576-17581.
3. Kohrman DC, Smith MR, Goldin, AL, et al. A missense mutation in the sodium channel gene Scn8a is responsible for cerebellar ataxia in the mouse mutant jolting. *J Neurosci* 1996b;16:5993-5999.
4. Veeramah KR, O'Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. *Am J Hum Genet* 2012;90:502-510.
5. Wagnon JL, Korn MJ, Parent R, et al. Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy. *Hum Mol Genet* 2015;24:506-515.
6. Meisler MH, Helman G, Hammer MF, et al. *SCN8A* Encephalopathy: Research Progress and Prospects. *Epilepsia* 2016;57:1027-1035
7. Wagnon JL, Meisler MH. Recurrent and Non-Recurrent Mutations of SCN8A in Epileptic Encephalopathy. *Front Neurol* 2015;6:104.
8. Wagnon JL, Barker BS, Hounshell JA, et al. Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy. *Ann Clin Transl Neurol* 2016;3:114-123.



9. Bunton-Stasyshyn RKA, Wagnon JL, Wengert ER, et al. Prominent role of forebrain excitatory neurons in *SCN8A* encephalopathy. *BRAIN* 2019;in press.
10. Jones JM, Meisler MH. Modeling human epilepsy by TALEN targeting of mouse sodium channel *Scn8a*. *Genesis* 2014;52:141-148.
11. Lopez-Santiago LF, Yuan Y, Wagnon JL, et al. Neuronal hyperexcitability in a mouse model of *SCN8A* encephalopathy. *Proc. Nat'l. Acad. Sci.* 2017;114:2383-2388.
12. Ottolini M, Barker BS, Gaykema RP, et al. Aberrant Sodium Channel Currents and Hyperexcitability of Medial Entorhinal Cortex Neurons in a Mouse Model of *SCN8A* Encephalopathy. *J. Neurosci.* 2017;37:7643-7655.
13. Noujaim SF, Kaur K, Milstein M, et al. A null mutation of the neuronal sodium channel *Nav1.6* disrupts action potential propagation and excitation-contraction coupling in the mouse heart. *FASEB J.* 2012; 26:63-72.
14. Frasier CR, Wagnon JL, Bao Y, et al. Cardiac arrhythmia in a mouse model of *SCN8A* Epileptic Encephalopathy. *Proc. Nat'l. Acad. Sci.* 2016.113:12838-12843.
15. Sprissler RS, Wagnon JL, Bunton-Stasyshyn RK, et al. Altered gene expression profile in a mouse model of *Scn8a* epilepsy reveals reactive astrogliosis in response to seizures. *Exptl. Neurol.* 2016;288:134-141.
16. Yu FH, Mantegazza M, Westenbroek RE et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. *Nat Neurosci.* 2006; 9:1142-1149
17. Anderson LL, Thompson CH, Hawkins NA, et al. Antiepileptic activity of preferential inhibitors of persistent sodium current. *Epilepsia.* 2014;55:1274-1283.

18. Royeck M, Horstmann MT, Remy S, et al. Role of axonal Nav1.6 sodium channels in action potential initiation of CA1 pyramidal neurons. *J Neurophysiol.* 2008. 100:2361-2380.
19. Osorio N, Cathala L, Meisler MH et al. Persistent Nav1.6 current at axon initial segments tunes spike timing of cerebellar granule cells. *J Physiol.* 2010. 588(Pt 4):651-70.
20. Enomoto A, Han JM, Hsiao CF, et al. Sodium currents in mesencephalic trigeminal neurons from Nav1.6 null mice. *J Neurophysiol.* 2007. 98:710-719.
21. Baker EM, Thompson CH, Hawkins NA, et al. The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of *SCN8A* encephalopathy. *Epilepsia* 2018;59:1166-1176.
22. Anderson LL, Hawkins NA, Thompson CH, et al. Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome. *Sci Rep.* 2017;7:1682.
23. Roovers J, De Jonghe P, Weckhuysen S. The therapeutic potential of RNA regulation in neurological disorders. *Expert Opin Ther Targets.* 2018; 22:1017-1028.
24. Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of *SCN8A* encephalopathy. *Neurology* 2015;84:480-489.
25. Gardella E, Becker F, Moller RS, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an *SCN8A* mutation. *Ann Neurol* 2016;79:428-436.
26. Wagnon JL, Barker BS, Ottolini M, et al. Loss-of-function mutations of *SCN8A* in intellectual disability without seizures. *Neurology Genetics* 2017;3:e170.
27. Wagnon JL, Mencacci NE, Barker BS, et al. Partial loss-of-function of sodium channel *SCN8A* in familial isolated myoclonus. *Human Mutation* 2018. 39:965-969.

28. Trudeau MM, Dalton JC, Day JW, et al. Heterozygosity for a protein truncation mutation of sodium channel *SCN8A* in a patient with cerebellar atrophy, ataxia and mental retardation. *J Med Genet.* 2006;43:527-530.
29. Sharkey LM, Jones JM, Hedera P, et al. *Parkinsonism Relat Disord.* Evaluation of *SCN8A* as a candidate gene for autosomal dominant essential tremor. 2009; 15:321-323.

Table 1. Features of two mouse models of *SCN8A* encephalopathy. The N1768D mouse was generated by TALEN knock-in of the first described patient mutation<sup>7</sup>. The R1872W mouse carries a conditional allele of a recurrent human mutation that leads to lethality in early childhood<sup>11</sup>. Onset is the age at first observed seizure. Duration is the interval between first observed seizure and death.

	<b>N1768D/+</b>	<b>R1872W/+</b>
patients	ambulatory, verbal, SUDEP at 15 yrs	nonambulatory, nonverbal
ephysiology	impaired inactivation	more severely impaired
mouse model:	Knock-in to <i>Scn8a</i>	conditional knock-in
onset	2-4 months	2 weeks
duration, onset to death	1-2 week	10 sec to 2 week depends on CRE
penetrance	50-75%	100%

## Figure Legends

**Figure 1.** *SCN8A* mutations associated with epileptic encephalopathy. The protein structure of the four-domain sodium channel Na<sub>v</sub>1.6 is represented; each symbol represents a patient mutation. The positions of the two mutations studied in mouse models are indicated with arrows.

**Figure 2.** *In vivo* mouse model of the epileptic encephalopathy mutation *SCN8A*-N1768D. Knock-in of the patient mutation<sup>6</sup> results in seizures and death in 50% of heterozygous D/+ animals. Combination with a null allele (D/-) or homozygosity of the mutant allele (D/D) exacerbates the phenotype, demonstrating partial protection by the wildtype allele in heterozygous animals<sup>9</sup>.

**Figure 3.** Spontaneous firing of hippocampal neurons in brain slices from N1768D mice<sup>13</sup>.


**Figure 4.** The conditional mouse mutation *SCN8A*-R1872W. A. The targeting vector containing two copies of the final coding exon 26 of *Scn8a* was inserted into the endogenous gene. B. In the absence of CRE recombinase the wildtype exon 26a is expressed. Deletion of exon 26a by CRE initiates expression of the mutant exon 26b<sup>11</sup>.

**Figure 5.** Predominant role of excitatory neurons in *SCN8A* encephalopathy in the conditional R1872W mouse. Global pre-implantation activation of the mutant allele by EIIA-CRE results in seizure onset at 2 weeks of age followed rapidly by lethality. Activation of the mutant allele in excitatory forebrain neurons by *Emx1* CRE also results in 100% penetrance of seizures and death, approximately 4 weeks later than the EIIA-CRE. In contrast, activation by the GAD2 CRE in inhibitory neurons had no detectable pathogenicity<sup>11</sup>.


**Figure 6.** Rescue of *Scn8a*N1768D mice by GS967/Prax330. The polycyclic drug GS967/Prax330<sup>18</sup> was incorporated into pelleted food and fed to the heterozygous mutant

mice from the age of 1.5 months (pre-seizure onset) to 6 months. The mice were protected against seizures and neurotoxicity until removal of the drug<sup>19</sup>.  $p < 0.0001$  (Log rank). Disease penetrance was higher than in Figure 2; this represents experimental variability within the same mouse line.


Author Manuscript



Author Manuscript




epi\_14703\_f2.tiff




epi\_14703\_f3.tiff





epi\_14703\_f4.tif



epi\_14703\_f5.tif

